Nektar Therapeutics
Symbool: 0UNL.L
LSE
1.65
USDMarktprijs vandaag
-1.1419
Koers/Winst Verhouding
0.0069
Koers/Winst Groei Verhouding
302.98M
MRK Kapitalisatie
- 0.00%
DIV Rendement
Nektar Therapeutics (0UNL-L) Jaarrekeningen
Balans
common:word.in-mln USD Growth | TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
balance-sheet.row.cash-and-short-term-investments | 0 | 303.6 | 505 | 734 | ||||||||||||
balance-sheet.row.short-term-investments | 0 | 283.5 | 438.1 | 719.7 | ||||||||||||
balance-sheet.row.net-receivables | 0 | 2.3 | 6 | 23.9 | ||||||||||||
balance-sheet.row.inventory | 0 | 16.1 | 19.2 | 15.8 | ||||||||||||
balance-sheet.row.other-current-assets | 0 | 8.7 | 15.8 | 21.9 | ||||||||||||
balance-sheet.row.total-current-assets | 0 | 330.7 | 546 | 795.6 | ||||||||||||
balance-sheet.row.property-plant-equipment-net | 0 | 36.9 | 85.9 | 177.5 | ||||||||||||
balance-sheet.row.goodwill | 0 | 0 | 76.5 | 76.5 | ||||||||||||
balance-sheet.row.intangible-assets | 0 | 0 | 0 | 0 | ||||||||||||
balance-sheet.row.goodwill-and-intangible-assets | 0 | 0 | 76.5 | 76.5 | ||||||||||||
balance-sheet.row.long-term-investments | 0 | 25.8 | 0 | 64.8 | ||||||||||||
balance-sheet.row.tax-assets | 0 | 0 | 0 | 0 | ||||||||||||
balance-sheet.row.other-non-current-assets | 0 | 4.6 | 2.2 | 2.7 | ||||||||||||
balance-sheet.row.total-non-current-assets | 0 | 67.3 | 164.6 | 321.6 | ||||||||||||
balance-sheet.row.other-assets | 0 | 0 | 0 | 0 | ||||||||||||
balance-sheet.row.total-assets | 0 | 398 | 710.6 | 1117.2 | ||||||||||||
balance-sheet.row.account-payables | 0 | 9.8 | 13 | 9.7 | ||||||||||||
balance-sheet.row.short-term-debt | 0 | 19.3 | 18.7 | 17.4 | ||||||||||||
balance-sheet.row.tax-payables | 0 | 0 | 0 | 0 | ||||||||||||
balance-sheet.row.long-term-debt-total | 0 | 112.6 | 126.5 | 148.1 | ||||||||||||
Deferred Revenue Non Current | 0 | 0 | 0 | 0 | ||||||||||||
balance-sheet.row.deferred-tax-liabilities-non-current | 0 | - | - | - | ||||||||||||
balance-sheet.row.other-current-liab | 0 | 22.2 | 36.6 | 58 | ||||||||||||
balance-sheet.row.total-non-current-liabilities | 0 | 215.8 | 275.8 | 352.5 | ||||||||||||
balance-sheet.row.other-liabilities | 0 | 0 | 0 | 0 | ||||||||||||
balance-sheet.row.capital-lease-obligations | 0 | 98.5 | 112.8 | 125.7 | ||||||||||||
balance-sheet.row.total-liab | 0 | 267 | 344 | 437.7 | ||||||||||||
balance-sheet.row.preferred-stock | 0 | 0 | 0 | 0 | ||||||||||||
balance-sheet.row.common-stock | 0 | 0 | 0 | 0 | ||||||||||||
balance-sheet.row.retained-earnings | 0 | -3477.2 | -3201.2 | -2833 | ||||||||||||
balance-sheet.row.accumulated-other-comprehensive-income-loss | 0 | 0.1 | -6.9 | -4.2 | ||||||||||||
balance-sheet.row.other-total-stockholders-equity | 0 | 3608.1 | 3574.7 | 3516.6 | ||||||||||||
balance-sheet.row.total-stockholders-equity | 0 | 131 | 366.6 | 679.5 | ||||||||||||
balance-sheet.row.total-liabilities-and-stockholders-equity | 0 | 398 | 710.6 | 1117.2 | ||||||||||||
balance-sheet.row.minority-interest | 0 | 0 | 0 | 0 | ||||||||||||
balance-sheet.row.total-equity | 0 | 131 | 366.6 | 679.5 | ||||||||||||
balance-sheet.row.total-liabilities-and-total-equity | 0 | - | - | - | ||||||||||||
Total Investments | 0 | 309.3 | 438.1 | 784.5 | ||||||||||||
balance-sheet.row.total-debt | 0 | 230.4 | 258 | 291.3 | ||||||||||||
balance-sheet.row.net-debt | 0 | 210.2 | 191.1 | 277 |
Kasstroomoverzicht
common:word.in-mln USD Growth | TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
cash-flows.row.net-income | 0 | -276.1 | -368.2 | -523.8 | ||||||||||||
cash-flows.row.depreciation-and-amortization | 0 | 7.8 | 12.2 | 13 | ||||||||||||
cash-flows.row.deferred-income-tax | 0 | -0.1 | 2.7 | -106.6 | ||||||||||||
cash-flows.row.stock-based-compensation | 0 | -13 | 57.3 | 94.7 | ||||||||||||
cash-flows.row.change-in-working-capital | 0 | -19.8 | 0.5 | -23.1 | ||||||||||||
cash-flows.row.account-receivables | 0 | 4.8 | 16.5 | 12.4 | ||||||||||||
cash-flows.row.inventory | 0 | 0.7 | -3.4 | -0.5 | ||||||||||||
cash-flows.row.account-payables | 0 | -2.9 | 3.1 | -11.7 | ||||||||||||
cash-flows.row.other-working-capital | 0 | -22.4 | -15.7 | -23.3 | ||||||||||||
cash-flows.row.other-non-cash-items | 0 | 108.6 | -8.5 | 133.1 | ||||||||||||
cash-flows.row.net-cash-provided-by-operating-activities | 0 | 0 | 0 | 0 | ||||||||||||
cash-flows.row.investments-in-property-plant-an-equipment | 0 | -0.9 | -5.7 | -15 | ||||||||||||
cash-flows.row.acquisitions-net | 0 | 1.2 | 13.2 | -217.8 | ||||||||||||
cash-flows.row.purchases-of-investments | 0 | -511.7 | -467.9 | -960.7 | ||||||||||||
cash-flows.row.sales-maturities-of-investments | 0 | 650.9 | 826.2 | 1178.5 | ||||||||||||
cash-flows.row.other-investing-activites | 0 | 0 | 0 | 217.8 | ||||||||||||
cash-flows.row.net-cash-used-for-investing-activites | 0 | 139.6 | 365.8 | 202.8 | ||||||||||||
cash-flows.row.debt-repayment | 0 | 0 | 0 | 0 | ||||||||||||
cash-flows.row.common-stock-issued | 0 | 0 | 0.8 | 33.2 | ||||||||||||
cash-flows.row.common-stock-repurchased | 0 | 0 | 0 | 0 | ||||||||||||
cash-flows.row.dividends-paid | 0 | 0 | 0 | 0 | ||||||||||||
cash-flows.row.other-financing-activites | 0 | 0 | 0.8 | 3 | ||||||||||||
cash-flows.row.net-cash-used-provided-by-financing-activities | 0 | 0 | 1.5 | 36.2 | ||||||||||||
cash-flows.row.effect-of-forex-changes-on-cash | 0 | 6.3 | -0.3 | -0.1 | ||||||||||||
cash-flows.row.net-change-in-cash | 0 | -46.7 | 52.5 | -175.1 | ||||||||||||
cash-flows.row.cash-at-end-of-period | 0 | 20.2 | 66.8 | 14.3 | ||||||||||||
cash-flows.row.cash-at-beginning-of-period | 0 | 66.8 | 14.3 | 189.3 | ||||||||||||
cash-flows.row.operating-cash-flow | 0 | -192.6 | -304 | -412.7 | ||||||||||||
cash-flows.row.capital-expenditure | 0 | -0.9 | -5.7 | -15 | ||||||||||||
cash-flows.row.free-cash-flow | 0 | -193.5 | -309.7 | -427.6 |
Rij winst-en-verliesrekening
common:word.in-mln USD Growth | TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
income-statement-row.row.total-revenue | 0 | 90.1 | 92.1 | 101.9 | ||||||||||||
income-statement-row.row.cost-of-revenue | 0 | 36.6 | 29.1 | 34.7 | ||||||||||||
income-statement-row.row.gross-profit | 0 | 53.5 | 62.9 | 67.2 | ||||||||||||
income-statement-row.row.gross-profit-ratio | 0 | 0 | 0 | 0 | ||||||||||||
income-statement-row.row.research-development | 0 | - | - | - | ||||||||||||
income-statement-row.row.selling-general-administrative | 0 | - | - | - | ||||||||||||
income-statement-row.row.selling-and-marketing-expenses | 0 | - | - | - | ||||||||||||
income-statement-row.row.other-expenses | 0 | 0 | 0 | 0 | ||||||||||||
income-statement-row.row.operating-expenses | 0 | 190.9 | 303.2 | 513.3 | ||||||||||||
income-statement-row.row.cost-and-expenses | 0 | 227.5 | 332.3 | 548 | ||||||||||||
income-statement-row.row.interest-income | 0 | 19 | 22.2 | 44.7 | ||||||||||||
income-statement-row.row.interest-expense | 0 | 25.3 | 28.9 | 47.3 | ||||||||||||
income-statement-row.row.selling-and-marketing-expenses | 0 | - | - | - | ||||||||||||
income-statement-row.row.total-other-income-expensenet | 0 | -138.8 | -124.7 | -77.2 | ||||||||||||
income-statement-row.row.ebitda-ratio-caps | 0 | - | - | - | ||||||||||||
income-statement-row.row.other-operating-expenses | 0 | 0 | 0 | 0 | ||||||||||||
income-statement-row.row.total-operating-expenses | 0 | -138.8 | -124.7 | -77.2 | ||||||||||||
income-statement-row.row.interest-expense | 0 | 25.3 | 28.9 | 47.3 | ||||||||||||
income-statement-row.row.depreciation-and-amortization | 0 | 7.8 | 12.2 | 13 | ||||||||||||
income-statement-row.row.ebitda-caps | 0 | - | - | - | ||||||||||||
income-statement-row.row.operating-income | 0 | -137.4 | -240.2 | -446.1 | ||||||||||||
income-statement-row.row.income-before-tax | 0 | -276.3 | -365 | -523.3 | ||||||||||||
income-statement-row.row.income-tax-expense | 0 | -0.2 | 3.2 | 0.6 | ||||||||||||
income-statement-row.row.net-income | 0 | -276.1 | -368.2 | -523.8 |
Vaak gestelde vragen
Wat is Nektar Therapeutics (0UNL.L) totale activa?
Nektar Therapeutics (0UNL.L) totale activa is 398033000.000.
Wat is de jaarlijkse omzet van de onderneming?
De jaarlijkse omzet is N/A.
Wat is de winstmarge van de onderneming?
De bedrijfswinstmarge is 0.625.
Wat is vrije kasstroom van de onderneming?
De vrije kasstroom is {free_cash_flow}}.
Wat is de nettowinstmarge van de onderneming?
De nettowinstmarge is -3.063.
Wat is de totale omzet van de onderneming?
De totale opbrengst is -1.500.
Wat is Nektar Therapeutics (0UNL.L) nettowinst (netto-inkomen)?
De nettowinst is -276056000.000.
Wat is de totale schuld van het bedrijf?
De totale schuld is 230401000.000.
Wat zijn de bedrijfskosten?
De bedrijfsuitgaven zijn 190903000.000.
Wat is het kasstroomcijfer van het bedrijf?
Enretprise cash is 0.000.